Citadel Advisors LLC Acquires New Shares in OnKure Therapeutics (NASDAQ:OKUR)

Citadel Advisors LLC acquired a new stake in shares of OnKure Therapeutics (NASDAQ:OKUR) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 1,074,314 shares of the company’s stock, valued at approximately $8,782,000. Citadel Advisors LLC owned 0.32% of OnKure Therapeutics as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in OKUR. Barclays PLC bought a new position in OnKure Therapeutics in the 4th quarter valued at $75,000. Walleye Capital LLC bought a new position in shares of OnKure Therapeutics in the fourth quarter worth $116,000. XTX Topco Ltd bought a new stake in OnKure Therapeutics during the fourth quarter valued at $160,000. Northern Trust Corp bought a new stake in OnKure Therapeutics during the fourth quarter valued at $165,000. Finally, 683 Capital Management LLC bought a new stake in OnKure Therapeutics during the fourth quarter valued at $373,000. Institutional investors own 90.98% of the company’s stock.

Insider Buying and Selling

In other OnKure Therapeutics news, major shareholder Cormorant Asset Management, Lp sold 24,300 shares of the business’s stock in a transaction on Monday, May 12th. The shares were sold at an average price of $1.99, for a total value of $48,357.00. Following the completion of the sale, the insider now directly owns 1,813,439 shares of the company’s stock, valued at $3,608,743.61. The trade was a 1.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold 28,296 shares of company stock worth $60,106 in the last quarter. 2.30% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on OKUR shares. Oppenheimer decreased their target price on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 11th. Evercore ISI initiated coverage on shares of OnKure Therapeutics in a research report on Wednesday, April 30th. They issued an “outperform” rating on the stock. Finally, HC Wainwright decreased their price objective on shares of OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating on the stock in a research report on Tuesday, March 18th. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $32.33.

OnKure Therapeutics Stock Down 0.5%

OKUR opened at $1.83 on Thursday. The business’s fifty day simple moving average is $3.41 and its 200 day simple moving average is $7.62. OnKure Therapeutics has a 52 week low of $1.70 and a 52 week high of $20.00. The stock has a market cap of $24.59 million, a PE ratio of -0.15 and a beta of 0.40.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.19) EPS for the quarter, beating the consensus estimate of ($1.41) by $0.22. As a group, equities analysts anticipate that OnKure Therapeutics will post -4.05 earnings per share for the current year.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.